Brian D Fox

US Patent:

6716965, Apr 6, 2004

Filed:

Nov 29, 2001

Appl. No.:

09/997610

Inventors:

Brian A. Fox - Seattle WA
James L. Holloway - Seattle WA

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C07K 1400

US Classification:

530350

Abstract:

The present invention relates to polynucleotide and polypeptide molecules for zacrp13, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp13 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp13 protein or fragments thereof.

US Patent:

6887695, May 3, 2005

Filed:

Mar 27, 2002

Appl. No.:

10/109084

Inventors:

Brian A. Fox - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12N009/10
C12P021/06

US Classification:

435193, 435 691

Abstract:

Transglutaminase polypeptides, polynucleotides encoding them, methods of making them, and methods of using them are disclosed. The polypeptides comprise residues 1-X of SEQ ID NO:2, wherein X is an integer from 462 to 704, inclusive. The compositions and methods of the invention may be used for a variety of purposes in industry, research, and medicine.

US Patent:

6914135, Jul 5, 2005

Filed:

Dec 9, 2002

Appl. No.:

10/315432

Inventors:

Paul O. Sheppard - Granite Falls WA, US
Brian A. Fox - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C07H021/02
C12Q001/34

US Classification:

536 231, 435 691, 4353201, 4352523, 435325, 435 18

Abstract:

Proteinase inhibitors comprising a Kunitz domain are disclosed. The Kunitz domain comprises a motif of amino acid residues as shown in SEQ ID NO:4, and the sequence of the Kunitz domain is shown in residues 57 through 107 of SEQ ID NO:2. The polypeptide also includes an N-terminal collagen domain in which a von Willebrand domain resides, and is shown in SEQ ID NO: 5. Also disclosed are methods for making the proteinase inhibitors, and expression vectors and cultured cells that are useful within the methods. The proteinase inhibitors may be used as components of cell culture media, in protein purification, and as inhibitors of protease degradation of plasma proteins.

US Patent:

6927040, Aug 9, 2005

Filed:

Jun 29, 2001

Appl. No.:

09/895834

Inventors:

Paul O. Sheppard - Granite Falls WA, US
Scott R. Presnell - Tacoma WA, US
Brian A. Fox - Seattle WA, US
Teresa Gilbert - Seattle WA, US
Betty A. Haldeman - Seattle WA, US
Francis J. Grant - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12P021/06
C12N015/21
C07H021/04

US Classification:

435 691, 435695, 435 6951, 435 701, 4353201, 435325, 536 235, 536 2352, 536 241

Abstract:

The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.

US Patent:

6955899, Oct 18, 2005

Filed:

Oct 17, 2003

Appl. No.:

10/688570

Inventors:

Brian A. Fox - Seattle WA, US
James L. Holloway - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C07K014/00
C12P021/06
C07H021/04

US Classification:

435 691, 530300, 530356, 514 12

Abstract:

The present invention relates to polynucleotide and polypeptide molecules for zacrp13, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp13 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp13 protein or fragments thereof.

US Patent:

7038032, May 2, 2006

Filed:

Apr 19, 2002

Appl. No.:

10/127816

Inventors:

Paul O. Sheppard - Granite Falls WA, US
Brian A. Fox - Seattle WA, US
Kevin M. Klucher - Bellevue WA, US
David W. Taft - Kirkland WA, US
Wayne Kindsvogel - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C07H 21/04
C07H 21/02
C12P 21/06

US Classification:

536 235, 536 231, 435 691

Abstract:

The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.

US Patent:

7071299, Jul 4, 2006

Filed:

Jun 18, 2001

Appl. No.:

09/883727

Inventors:

Robert R. West - Seattle WA, US
Paul O. Sheppard - Granite Falls WA, US
Brian A. Fox - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C07K 7/06
C07K 7/08
C07K 14/435

US Classification:

530324, 530325, 530326, 530327, 530328, 530329, 530330

Abstract:

The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such moieties, which can be used to treat conditions characterized by inappropriate complement activation.

US Patent:

7122351, Oct 17, 2006

Filed:

Oct 18, 2002

Appl. No.:

10/274638

Inventors:

Margaret Dow Moore - Seattle WA, US
Brian A. Fox - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12N 5/10
C12N 15/16
C12N 15/63

US Classification:

435 694, 4352523, 43525411, 4353201, 536 234, 536 235, 536 2351

Abstract:

Proteins consisting of two PDGF-D polypeptide chains, polynucleotides encoding the polypeptides, and materials and methods for making the proteins are disclosed. Each of the polypeptide chains consists of, from amino terminus to carboxyl terminus, the following operably linked segments: P1-P2-h-C2-C3; P1-P2-C2-C3; h-C2-C3-P2-P1; or C2-C3-P2-P1. Within these polypeptide chains, P1 is a first polypeptide segment as shown in SEQ ID NO:2 or SEQ ID NO:4 from amino acid x to amino acid y, wherein x is an integer from 246 to 258, inclusive, and y is an integer from 365–370, inclusive; P2 is a second polypeptide segment consisting of from 4 to 20 amino acid residues; h is an immunoglobulin hinge region or portion thereof; and C2 and C3 are C2 and C3 domains of an immunoglobulin heavy chain, respectively. Within the protein, the two polypeptide chains are joined by one or more disulfide bonds, each of the chains is optionally glycosylated, and the protein binds to and activates cell-surface PDGF receptors.